Category Archives: Stem Cell Doctors


Bluebird Bios first gene therapy for rare blood disease wins FDA approval – The Boston Globe

Zynteglo could change that by providing a healthy copy of the essential beta-globin gene to blood stem cells, allowing their bodies to make healthy blood cells and eliminate the need for regular transfusions. In clinical trials, about 90 percent of patients who got the one-time therapy no longer needed transfusions to treat their disease.

Dr. David A. Williams, chief of hematology/oncology at Boston Childrens Hospital, was impressed with the effectiveness of the therapy. This is clearly very clinically meaningful for the patients, he said.

Before Zynteglos approval, stem cell transplants were the only potentially curative options for people with beta thalassemia, but many people with the condition are unable to find a genetically-matched donor. Doctors who treat people with the condition were excited by the approval of Zynteglo.

This is really huge. The idea that now you have the option of a curative therapy for all patients is enormous, said Dr. Sujit Sheth, chief of the division of pediatric hematology/oncology at Weill Cornell Medicine.

Sheth noted that stem cell transplants carry the risk of immune rejection, which can be deadly. You have a far lower risk of complications from getting your own cells back than if youre getting it from someone else, he said.

Bluebird estimates that there are as many as 1,500 people with transfusion-dependent beta thalassemia in the United States. Thomas Klima, the firms chief commercial officer, told the Globe that as many as 850 of them may qualify for Zynteglo.

The firm expects about one-third of those patients to be pretty eager to get therapy, Klima added. Another third may need more information and time to think it over, and the final third may consider their current transfusion treatments fine.

Despite the relatively modest numbers of patients who may get the therapy, the approval is a major win for Bluebird, which has faced a series of troubles over the past few years that brought its stock falling about 98 percent from its peak in 2018. The firm said it would lay off 30 percent of its employees in April and warned investors it only had enough cash to last until the first half of 2023.

Over the last year we faced so many challenges, Klima said. But the group thats here now and the group thats getting ready to launch our gene therapies couldnt be more thrilled.

The therapy is made from a patients own blood stem cells collected during a hospital visit and shipped to the contract manufacturing firm Lonza, just south of Houston, TX. Once there, scientists will treat the cells with Bluebirds gene therapy, made from a lentivirus that shuttles the beta-globin gene into the cells.

After a quality check, cells are shipped back to the hospital. Before getting the altered cells infused, a patient must undergo chemotherapy to clear out space in their bone marrow for the new cells to engraft. Once they take hold, they will make new healthy red blood cells for years, potentially indefinitely.

Craig Butler, national executive director of the Cooleys Anemia Foundation a nonprofit patient organization for thalassemia is excited for people to have an alternative to time-consuming transfusions.

Its usually a full day process for someone, which means that theyre missing a day of work or a day of school, he said. The approval of Zynteglo means that they will no longer have to be bound to transfusions for the rest of their lives.

Wanda Sihanath, 26, was one of the first people to get the therapy in a clinical trial in 2014. She hasnt needed a transfusion in over eight years. It feels like really great not to be tethered to hospital and having to check in at least once a month, she said.

Sihanath, who lives in San Jose, was excited to hear that Zynteglo is approved. I am super stoked, she said, and is hopeful that the therapy will help untether people from regular hospital visits.

But the chemotherapy Sihanath got to prepare her body for the gene therapy may have affected her fertility, and she wishes she would have sought a little more counseling about getting the procedure at a young age. Doctors say that some young people may wish to hold off on getting the therapy.

The therapy will only be offered at a small number of centers across the United States, including at Boston Childrens Hospital.

Colleen Dansereau, the hospitals director of clinical operations of the gene therapy program, anticipates that the hospital will be ready to start the treatment procedure for a patient by September. But she anticipates it could take longer for Bluebird to get ready and for insurers to guarantee payment for the therapy.

Boston Childrens regularly provides transfusions for about 45 people with the condition, plus additional patients referred from other centers, Dansereau said.

The hospital may end up treating additional patients with beta thalassemia from other parts of the world where the disease is more prevalent, including the Middle East and Southeast Asia, Dansereau added. We anticipate that we could have an increase in our international services for this particular product.

Zynteglo is the third gene therapy approved by the FDA. The Roche gene therapy Luxturna, which treats a genetic eye disease, was approved in 2017 with a price tag of $850,000. The Novartis gene therapy Zolgensma, which treats spinal muscular atrophy, was approved in 2019 with a cost of $2.1 million. The FDA could approve a fourth gene therapy, also made by Bluebird, in September.

Ryan Cross can be reached at ryan.cross@globe.com. Follow him on Twitter @RLCscienceboss.

Continued here:
Bluebird Bios first gene therapy for rare blood disease wins FDA approval - The Boston Globe

Molecular Map Reveals Insights Into the Genetic Drivers of CLL – The ASCO Post

By The ASCO Post Staff Posted: 8/16/2022 2:43:00 PM Last Updated: 8/16/2022 3:15:33 PM

A newly constructed map of the landscape of genetic changes in chronic lymphocytic leukemia (CLL) may provide a better understanding of this complex malignancy that could lead to more accurate prognoses for patients, improved diagnostics, and novel treatments. These research findings were published by Knisbacher et al in Nature Genetics, and the study was conducted by an international collaboration of investigators, including teams from the Mass General Cancer Center, the Dana-Farber Cancer Institute, and the Broad Institute of MIT and Harvard.

CLL exists as either a slowly or rapidly growing cancer and has been linked to certain genetic mutations, but it has yet to be fully characterized. Previous analyses have provided only fragments of a CLL map, each focusing on particular types of patients or limited data. To provide a more thorough understanding of the biological underpinnings of CLL and its molecular subtypes, scientists set out to construct a map from the largest CLL data set to date. To build the CLL map, the team analyzed variations in genetic sequences, gene-expression patterns, and chemical modifications to DNAor genomic, transcriptomic, and epigenomic datafrom 1,148 patients.

Such a CLL map could eventually be leveraged in the clinic, wherein the genomic features of new patients can be compared with the treatments and outcomes of patients with similar genetic profiles, said co-senior and co-corresponding author Catherine Wu, MD, Chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. This profiling could potentially help more accurately tailor prognosis and treatment of a new patient based on their particular molecular features, getting closer to precision medicine.

Key Findings

The scientists identified 202 genes109 of which were novelthat when mutated, could potentially drive CLL, and they refined the characterization of subtypes of CLL with distinct genomic characteristics and prognoses. Beyond genetic sequences, the expression patterns of certain genes further subcategorized CLL and provided valuable prognostic information.

Our study has revealed that the genetic and biologic landscape of CLL is more complex than previously appreciated, said co-senior and co-corresponding author Gad Getz, PhD, Director of Bioinformatics at the Mass General Cancer Center and Director of the Cancer Genome Computational Analysis group at the Broad Institute. Patients clinical outcomes were associated with a combination of genomic, transcriptomic, and epigenomic featuresintegrating these data could predict a patients likelihood of experiencing remission vs developing more advanced cancer.

We are releasing a CLL map portal that is based on the CLL map and will be an interactive website for translational researchers to use as a resource for further investigationsuch as learning more about the different drivers and subtypes of CLL, said Dr. Getz.

Disclosure: This work was supported by the National Institutes of Health and the Broad/IBM Cancer Resistance Research Project. For full disclosures of the study authors, visit nature.com.

View post:
Molecular Map Reveals Insights Into the Genetic Drivers of CLL - The ASCO Post

MESO NUMISMATICS, INC. Management’s Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) – Marketscreener.com

Forward-Looking Statements

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words "believes," "project," "expects," "anticipates," "estimates," "intends," "strategy," "plan," "may," "will," "would," "will be," "will continue," "will likely result," and similar expressions. We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of complying with those safe-harbor provisions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, cybersecurity, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Further, information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

Since the acquisition of Global Stem Cell Group in August last year, our focus has been mainly dedicated to its operations serving the markets in the regenerative medicine industry. We still have numismatics operation, but the overall plan for the company is too move from the sale of coins, paper currency, bullion and medals into what we believe is a more lucrative opportunity for our company.

We work with doctors and their staff to provide products, solutions, equipment, services, and training to help them be successful in the application of Stem Cell Therapies. Our team combines solutions from extensive clinical research with the manufacturing and commercialization of viable cell therapy and immune support related products that we believe will change the course of traditional medicine around the world forever. Our strategy allows us the ability to create immediate revenue streams through product sales, distribution, and clinical applications, driven by our extensive education platform. Our revenue comes directly from the training and the seminars, from the resale of these kits, products, and equipment, services, and from the reoccurring application of our process using the kits and solutions we provide.

Global Stem Cells Group is a leader in the Stem Cell and Regenerative Medicine fields, covering clinical research, patient applications, along with physician training through our state-of-the-art global network of companies. The Company's mission is to enable physicians to make the benefits of stem cell medicine a reality for patients around the world. They have been educating doctors on the science and application of cell-based therapeutics for the past 10 years. Our professional trademarked association "ISCCA" INTERNATIONAL SOCIETY FOR STEM CELL APPLICATION is a global network of medical professionals that leverages these multinational relationships to build best practices and further our mission.

The Company envisions the ability to improve "health-span" through the discovery and developments of new cellular therapy products, and cutting-edge technology.

Global Stem Cells Group, as almost everyone else in the world, was severely affected by the covid 19 pandemic. As we look to recover in 2022, we are integrating every aspect of the regenerative medicine industry. During 2022, we plan to add manufacturing and commercialization of viable cell therapy and immune support related products that we believe will change the course of traditional medicine around the world forever.

We believe this strategy will allow us the ability to increase our current revenues and create immediate revenue streams through product sales, distribution, and clinical applications, driven by our extensive education platform here are our main projects and revenue generators for 2022 and beyond.

Results of Operations for the Three Months Ended June 30, 2022 and 2021.

Revenue increased by 1,831% in the amount of $288,752 for the three months ended June 30, 2022, compared to the same period in 2021. The key reason for the increase in revenue was a result of the acquisition of Global Stem Cells Group, Inc. on August 18, 2021. Revenue from viable cell therapy and immune support related products along with physician training was $297,521 and a decrease in sale of coins, metals and paper money of $8,769 for the three months ended June 30, 2022, compared to the same period in 2021.

Listed below are the revenues, cost of revenues and gross profits by Company for the three months ended June 30, 2022:

We expect to increase our revenues in future quarters from our operations associated with Global Stem Cells with less expected revenues in future quarters associated with our numismatic operations.

Operating expenses increased by 99% in the amount of $255,634 for the three months ended June 30, 2022, compared to the same period in 2021. Listed below are the major changes to operating expenses:

Advertising and marketing fees increased by $80,817 for the three months ended June 30, 2022, compared to the same period in 2021, primarily due to the acquisition of Global Stem Cells Group, Inc. on August 18, 2021.

Depreciation and amortization increased by $35,125 for the three months ended June 30, 2022, compared to the same period in 2021, primarily due to completion of Cancun lab in May 2022.

General and administrative expense increase by $125,359 for the three months ended June 30, 2022, compared to the same period in 2021, primarily due to the acquisition of Global Stem Cells Group, Inc. on August 18, 2021.

Other expense increased by $456,085 for the three months ended June 30, 2022, compared to the same period in 2021, primarily as a result of the increase in interest on promissory notes. During the six months ended June 30, 2021, we received $11,400,000 in proceeds received from the issuance of promissory notes. We expect other expense to increase in future quarters as a result of the interest on the new debt.

We recorded a net loss of $1,493,065 for the three months ended June 30, 2022, as compared with a net loss of $926,077 for the same in 2021.

Results of Operations for the Six Months Ended June 30, 2022 and 2021.

Revenue increased by 2,941% in the amount of $594,387 for the six months ended June 30, 2022, compared to the same period in 2021. The key reason for the increase in revenue was a result of the acquisition of Global Stem Cells Group, Inc. on August 18, 2021. Revenue from viable cell therapy and immune support related products along with physician training was $596,270 and a decrease in sale of coins, metals and paper money of $1,883 for the six months ended June 30, 2022, compared to the same period in 2021.

Listed below are the revenues, cost of revenues and gross profits by Company for the six months ended June 30, 2022:

We expect to increase our revenues in future quarters from our operations associated with Global Stem Cells with less expected revenues in future quarters associated with our numismatic operations.

Operating expenses increased by 190% in the amount of $761,900 for the six months ended June 30, 2022, compared to the same period in 2021. Listed below are the major changes to operating expenses:

Advertising and marketing fees increased by $135,194 for the six months ended June 30, 2022, compared to the same period in 2021, primarily due to the acquisition of Global Stem Cells Group, Inc. on August 18, 2021.

Professional fees increased by $262,824 for the six months ended June 30, 2022, compared to the same period in 2021, primarily due to audit and accounting expenses.

Depreciation and amortization increased by $61,902 for the six months ended June 30, 2022, compared to the same period in 2021, primarily due to completion of Cancun lab in May 2022.

General and administrative expense increase by $216,667 for the six months ended June 30, 2022, compared to the same period in 2021, primarily due to the acquisition of Global Stem Cells Group, Inc. on August 18, 2021.

Other expense increased by $1,271,308 for the six months ended June 30, 2022, compared to the same period in 2021, primarily as a result of the increase in interest on promissory notes. During the six months ended June 30, 2021, we received $11,400,000 in proceeds received from the issuance of promissory notes. We expect other expense to increase in future quarters as a result of the interest on the new debt.

We recorded a net loss of $3,170,029 for the six months ended June 30, 2022, as compared with a net loss of $1,398,384 for the same in 2021.

Liquidity and Capital Resources

Since inception, the Company has financed its operations through private placements and convertible notes. The following is a summary of the cash and cash equivalents as of June 30, 2022 and December 31, 2021.

Edgar Online, source Glimpses

Visit link:
MESO NUMISMATICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.com

Illinois Innovation Network honors innovators from across state – University of Illinois

The Illinois Innovation Network (IIN) announced recipients of its second-annual innovation awards Wednesday at the Illinois State Fairs Tech Prairie STEAM Expo, recognizing individuals from the IINs 15 hubs who have made key advances in research, technology commercialization and education.

The awards were presented to faculty, staff or scientists from IIN hubs in four of the IINs key subject areas: computing and data, environment and water, food and agriculture, and health and wellness. The IIN also presented awards for an open category of innovation and to a student innovator from IIN hubs.

It is our honor to celebrate these innovators and their discoveries, said Jay Walsh, vice president for economic development and innovation for the University of Illinois System, which coordinates the IIN. They all are shining examples of the fantastic research and discovery happening across our state.

Innovators were honored for developments in using numerous data streams to provide in-depth forecasting systems for agricultural ecosystems, the discovery and utilization of microbial biomes to produce new materials from organic waste, creating a new method to manufacture biodegradable plastic from agricultural biomass and food waste, and a new program that gives children the opportunity to gain real-life space exploration experience.

These innovators are an example of one of the things I love most about our state: we have brilliant people coming up with solutions to some of the worlds most difficult challenges, said Bruce Sommer, director of economic development and innovation at the University of Illinois Springfield, whose office facilitated the awards program. I am encouraged by the diversity of our recipients and the incredible work that they are doing.

IIN Innovation Award recipients Computing & Data Category Kaiyu Guan, Blue Waters associate professor in ecohydrology and remote sensing, University of Illinois Urbana-Champaign Dr. Guan developed the technology to observe and measure land and water resources for every farm on the planet, which powers his startup company Habiterre. Habiterre integrates data streams from satellites, airplanes, automobiles and ground sensor networks to create a comprehensive view of farmland. Those data streams are processed with the companys fusion algorithms, which eliminate gaps in the data and remove the effects of clouds, and have been verified with actual ground truth information, creating a quantitative analysis of individual fields at a 30-meter (100-foot) resolution and at a daily frequency, recording the past 20+ years. Then they apply scientific models and proprietary algorithms to evaluate crop growth conditions, water use, biochemical status, and management practices. Starting with a well-established scientific model for simulating entire agriculture ecosystems, Habiterre added proprietary improvements that incorporate hundreds of variables above and below ground, then it constrained the model with actual observations, create a reliable, realistic and holistic view of each farm. This effort has created the most advanced model for crop growth, carbon cycles, and nutrient dynamics. Using AI and advanced mathematical tools to combine the data and model, we have created the first real forecasting capabilities for agro-ecosystems. Habiterre can directly see how different components of carbon, water, and nutrients change during the growth season and how they are impacted by farming practices. Additionally, the company can create simulations that make it possible to predict the outcomes of various changes, from switching crop varieties and management practices, to assessing the impacts of climate change. With the aid of supercomputers and cloud computing, they can process millions of farm-level simulations simultaneously, allowing us to achieve field-level accuracy over large geographic areas.

Environment & Water Category Scott Hamilton-Brehm, associate professor in biological sciences, Southern Illinois University Carbondale Dr. Hamilton-Brehm is an innovator in the discovery and utilization of geothermal and subsurface microbial biomes to perform green remediation and recovery of organic waste to produce new materials and to produce value-added materials and food. Hamilton-Brehm holds two patents, led the student team that received funding as one of the finalists in the Carbon Removal XPRIZE competition, and was part of the team selected for funding through the NASA Deep Space Food Challenge. Dr. Hamilton-Brehm also led the efforts by SIU to produce for the State of Illinois over 100,000 vials of Viral Transport Medium (VTM) during the early days of the COVID-19 pandemic. The Carbon Removal XPRIZE award focused on the innovative use of Oxidative Hydrothermal Dissolution (OHD) to convert captured carbon, in the form of almost any plant-based waste biomass, into a water-soluble liquid. The resulting liquid can then be pumped into natural or man-made geologic recesses where microbes will eat the waste, thereby sequestering the carbon contained within the waste. The advantage of this approach over air-based carbon capture is dramatically revealed when one recognizes that one pound of raw plant matter contains about the same amount of carbon as one million liters of air. Hamilton-Brehm and his team were selected as one of the top 60 teams worldwide for the XPRIZE. More recently, Hamilton-Brehm and his team played a crucial role in obtaining funding from NASA through the Deep Space Food Challenge program to develop their next-generation food production system called Bites, which will utilize plastic and biomass waste as the carbon source for food generation.

Food & Agriculture Category Lahiru Jayakody, assistant professor in microbiology, Southern Illinois University Carbondale Dr. Jayakody is a young innovator in synthetic microbiology and green chemistry and holds or has applications for seven patents. His patents on engineering robust microbial cell factories apply to developing multiple technologies, including valorization of unconventional feedstock such as industrial-wastewater streams and waste plastic. He developed a novel thermo-bio-catalytic hybrid process to valorize untapped waste carbon in the agricultural biomass, i.e., high-toxic aldehydes and aromatics, industrial food waste, and waste plastic. His innovative approach merged engineered microbial-based biofunneling and biofunctionalization of organic substrates with Dr. Ken Anderson's (2021 IIN Innovation Award) Oxidative Hydrothermal Dissolution technology (OHD), to produce advanced platform chemicals to replace incumbent petrochemicals and microbial-based food ingredients for next-generation food production. Jayakody partnered with one of the world's leading green tea manufacturers, Ito En Japan, to develop and commercialize technology to manufacture novel biodegradable plastic from waste tea, coffee, and postconsumer polyethylene terephthalate (PET) bottles. The generated chemicals will be used to make advanced PET alternatives and smart food packaging materials. He also leads the team "Bites," which has invented a next-generation food production system using this technology. His innovative synthetic microbial-based process converts waste plastic into edible, 3D printed, customized, nutritious food for astronauts. His team was one of 18 winners of the Phase I NASA Deep Space Food Challenge and the only Illinois-based team.

Health & Wellness Category Mohammad Islam, research assistant professor in chemistry, University of Illinois Chicago Dr. Islam has recently engineered a cell-based method of preventing infection from the SARS-CoV-2 virus. Spike protein (S) of SARS-CoV-2 uses human receptor containing angiotensin-converting enzyme 2 (ACE2) cells to initiate viral entry into the body. By preventing the receptor binding domain (RBD) of S protein from binding with ACE2 cells, SARS-CoV-2 can be prevented from infecting the human body. Dr. Islam developed an ACE2 decoy receptor that binds with the RBD of SARS-CoV-2 spike protein with low nanomolar affinity and 10-fold affinity enhancement over the wildtype. Dr. Islam used computational mutagenesis and molecular dynamics simulations to design the soluble decoy ACE2, which is known as ACE2-FFWF. This research was published in the Journal of Chemical Information and Modelling, (J. Chem. Inf. Model. 61, 46564669) where Dr. Islam acted as the principal investigator and the corresponding author of the paper. Dr. Islams research develops and advances a new class of soluble sACE2 that can act as potential therapeutics against variants of concern, namely omicron, alpha, beta, delta, delta plus, and gamma.

Open Category Keith Jacobs, statewide 4-H STEM specialist, University of Illinois Extension Keith Jacobs is uniquely contributing to the recruitment, diversification and mentoring of the next generation workforce in computing and STEM. Jacobs designed a new program called 4-H in Space that gives middle and high school youth the opportunity to gain real-life experience in space exploration by building, programming, and launching real satellites into orbit. The students gain deep experience in subjects like coding, mechanical engineering and astronomy, all of which help hone their STEM skills. Jacobs expects to reach some 2,000 young people in this first year of the program, with a goal of reaching 10,000 young people by 2025. Additionally, Jacobs developed partnerships with the Laboratory for Advanced Space Systems in Illinois (LASSI), and the International Space Station national Laboratories (ISSNL) to create unique hands-on learning opportunities for youth in the program. A select group of youth the Illinois Mission Command team traveled to the Kennedy Space Center in Florida in July 2022, where they designed an experiment to be launched and tested on the International Space Station. In collaboration with the LASSI group in the University of Illinois Urbana-Champaigns Aerospace Engineering Department, Mission Control youth will code and launch a cube satellite in 2023. Youth will then monitor and analyze data received from the programmed sensors in space. The youth in Mission Control reflect the racial and ethnic diversity of Illinois, and reflect Jacobs commitment to inspiring under-represented youth to pursue STEM careers. Jacobs innovative program design is already being scaled to other states through the network of land-grant universities. To date, he has trained and mentored 4-H staff in three other states. In 2023, his curriculum 4-H in Space will be made available, with the potential reach the 7 million youth in 4-H across the country.

Student Category Pierre Paul, We Hear You, Distillery Labs Paul and his team have developed We Hear You, an AI-based sign language translator as well as a personalized automatic door opener fob for persons with disabilities that are accommodated under the Americans with Disabilities Act. Currently, the ADA guidelines only provide guidance based on the minimum standards and requirements that have to be met. We Hear You's mission is to improve the quality of life for persons with disabilities, and they are actively seeking to create solutions that proactively resolve the challenges that they continue to face even when there are accessible pathways throughout their daily journeys. Pierre and his team have validated the problem they're solving in providing innovative solutions that solve accessibility issues. They have won a number of competitions including the Social Innovation Challenge, and the Big Idea Competition while at Bradley University. Additionally, they have been incubated at Bravelaunch, gBETA Distillery Labs, and most recently at UIUCs iVenture Accelerator.

Excerpt from:
Illinois Innovation Network honors innovators from across state - University of Illinois

‘Amazing’ teenager needs stem cell donation to survive leukaemia – Sky News

The family of a teenager with leukaemia have urged people to sign up to the stem cell register, as a transplant is his only chance of survival.

The call for help from 16 to 30-year-old males is being made by the family of 14-year-old Daniel Greer, of Newry, County Down, who was diagnosed with acute myeloid leukaemia two months ago.

Doctors have said his only chance of survival is with a stem cell donation which would help rebuild his immune system.

Daniel has been staying at the Royal Belfast Hospital for Sick Children since his diagnosis and is being treated with aggressive chemotherapy.

Young men make up more than half of all stem cell transplants for blood cancer and blood disorder patients, but they make up just 18% of the register, according to the Anthony Nolan blood cancer charity, which is helping with the international appeal - dubbed the DoItForDaniel campaign.

His mother, Anne Greer, said: "Daniel is an amazing, bright young man who lights up any room he walks into.

"His wicked sense of humour keeps our spirits up, even now while he's in hospital receiving chemotherapy.

Households already owe 1.3bn to energy suppliers - even before winter bill hikes set in

UK weather latest updates: Fears number of deliberate fires will rocket in heatwave - while charity warns of damage to important landscapes and wildlife

Majority of babies born in England and Wales in 2021 were out of wedlock, new statistics reveal

"I know he's really proud that his story is inspiring people to sign up to the stem cell register.

"Those people will potentially help him, as well as many other people around the world who desperately need a stem cell transplant like Daniel."

Daniel complained of back and neck pain before a series of blood tests confirmed his illness.

Aggressive chemotherapy is being used to place him into remission, so he may be able to receive a transplant.

Only one in four people will find a match within their family. However, Daniel's older brother, James, is not a match and so he needs a stem cell transplant from an unrelated donor.

Home town support has so far included encouragement from pharmacies in Newry for people to sign up to the register.

There has also been an awareness-raising drive about stem cell donation at Belfast International Airport.

Anthony Nolan chief executive Henny Braund said: "Finding his matching donor would mean everything to Daniel and his family. We are committed to supporting Daniel as he waits for news of the donor who could save his life.

"Last year over 1,300 people around the world with blood cancer or a blood disorder were given a second chance of life because of the wonderful people that are signed up to the Anthony Nolan register.

"But too many people, like Daniel, are told there is no matching donor for them.

"Signing up to the register is quick and simple, and we urge anyone who is in good general health, especially young men aged 16-30, to come forward and potentially save the life of someone like Daniel."

People aged 16-30 can go online to join the Anthony Nolan register.

Read the original here:
'Amazing' teenager needs stem cell donation to survive leukaemia - Sky News

Factors that affect haemoglobin levels and how to detect when it’s low – Jamaica Gleaner

HAEMOGLOBIN IS a protein in your red blood cells. Your red blood cells carry oxygen throughout your body. If you have a condition that affects your bodys ability to make red blood cells, your haemoglobin levels may drop. Low haemoglobin levels may be a symptom of several conditions, including different kinds of anaemia and cancer.

If a disease or condition affects your bodys ability to produce red blood cells, your haemoglobin levels may drop. When your haemoglobin level is low, it means your body is not getting enough oxygen, making you feel very tired and weak.

Normal haemoglobin levels are different for men and women. For men, a normal level ranges between 14.0 grams per decilitre (gm/dL) and 17.5 gm/dL. For women, a normal level ranges between 12.3 gm/dL and 15.3 gm/dL. A severe low-haemoglobin level for men is 13.5 gm/dL or lower. For women, a severe low haemoglobin level is 12 gm/dL.

Your doctor diagnoses low haemoglobin by taking samples of your blood and measuring the amount of haemoglobin in it. This is a haemoglobin test. They may also analyse different types of haemoglobin in your red blood cells, or haemoglobin electrophoresis.

Several factors affect haemoglobin levels and the following situations may be among them:

Your body produces red blood cells and white blood cells in your bone marrow. Sometimes, conditions and diseases affect your bone marrows ability to produce or support enough red blood cells.

Your body produces enough red blood cells, but the cells are dying faster than your body can replace them.

You are losing blood from injury or illness. You lose iron any time you lose blood. Sometimes, women have low haemoglobin levels when they have their periods. You may also lose blood if you have internal bleeding, such as a bleeding ulcer.

Your body cannot absorb iron, which affects your bodys ability to develop red blood cells.

You are not getting enough essential nutrients like iron and vitamins B12 and B9.

Your bone marrow produces red blood cells. Diseases, conditions and other factors that affect red blood cell production include:

Lymphoma: This is a term for cancers in your lymphatic system. If you have lymphoma cells in your bone marrow, those cells can crowd out red blood cells, reducing the number of red blood cells.

Leukaemia: This is cancer of your blood and bone marrow. Leukaemia cells in your bone marrow can limit the number of red blood cells your bone marrow produces.

Anaemia: There are many kinds of anaemias involving low-haemoglobin levels. For example, if you have aplastic anaemia, the stem cells in your bone marrow dont create enough blood cells. In pernicious anaemia, an autoimmune disorder keeps your body from absorbing vitamin B12. Without enough B12, your body produces fewer red blood cells.

Multiple Myeloma: This causes your body to develop abnormal plasma cells that may displace red blood cells.

Chronic Kidney Disease: Your kidneys dont produce the hormone that signals to your bone marrow to make red blood cells. Chronic kidney disease affects this process.

Antiretroviral medications: These medications treat certain viruses. Sometimes these medications damage your bone marrow, affecting its ability to make enough red blood cells.

Chemotherapy: Chemotherapy may affect bone marrow cells, reducing the number of red blood cells your bone marrow produces.

Doctors treat low haemoglobin by diagnosing the underlying cause. For example, if your haemoglobin levels are low, your healthcare provider may do tests that reveal you have iron-deficiency anaemia. If that is your situation, they will treat your anaemia with supplements. They may recommend that you try to follow an iron-rich diet. In most cases, treating the underlying cause of anaemia will bring the haemoglobin level up.

Many things can cause low haemoglobin, and most of the time you cannot manage low haemoglobin on your own. But eating a vitamin-rich diet can help maintain your red blood cells. Generally, a balanced diet with a focus on important nutrients is the best way to maintain healthy red blood cells and haemoglobin.

keisha.hill@gleanerjm.comSOURCE: Centres for Disease Control and Prevention

Here is the original post:
Factors that affect haemoglobin levels and how to detect when it's low - Jamaica Gleaner

Why Glucose Restrictions Are Essential in Treating Cancer – The Epoch Times

The procedure recommended by most doctors might not always be a good option, as it could turn a potentially benign situation into a malignant one.

Thomas Seyfried, Ph.D., professor in the biology department at Boston College, is a leading expert and researcher in the field of cancer metabolism and nutritional ketosis. His book, Cancer as a Metabolic Disease: On the Origin, Management and Prevention of Cancer is a foundational textbook on this topic, and in August 2016, he received the Mercola.com Game Changer Award for his work.

Here, we discuss the mechanisms of cancer and the influence of mitochondrial function, which plays a crucial role in the development and treatment of this disease. Hislandmark cancer theory is available as a free PDF.

Many of his views are now encapsulated in his most paper,1Mitochondrial Substrate-Level Phosphorylation as Energy Source for Glioblastoma: Review and Hypothesis, published online December 27, 2018. Hes also published a number of other papers2,3,4on the metabolic underpinnings of cancer.

The paper is a review and hypothesis paper identifying the missing link in Otto Warburgs central theory,Seyfried explains. [Warburg] defined the origin of cancer very accurately back in the 1920s, 30s, 40s and 50s in his work in Germany. Basically, he argued and provided data showing that all cancer cells, regardless of tissue origin, were fermenters. They fermented lactic acid from glucose as a substrate.

Even in the presence of oxygen, these cells were fermenting. This is clearly a defect in oxidative phosphorylation. The problem is that for decades, people said Warburg was wrong mainly because we see a lot of cancer cells take up oxygen and make adenosine triphosphate (ATP) from within the mitochondria People began to question, If cancer cells have normal respiration, why would they want to use glucose as a fermentable fuel?

The whole concept became distorted The cancer cells simply choose to ferment rather than respire. Now, of course, if you look under the electron microscope at majority of cancers, youll see that the mitochondria are defective in a number of different ways. Their structures are abnormal. The numbers are abnormal. There are many abnormalities of mitochondria seen directly under electron microscopy. Clearly, Warburg was not wrong.

Before we delve into the meat of how cancer actually occurs it would be good to review a diagnostic strategy that nearly all of us are offered when confronted with a cancer diagnosis. It is vital to understand that this may not be your best strategy and that for many it would be wise to avoid the biopsy.

Seyfried warns against doing biopsies, as this procedure may actually cause the cancer to spread. A tumor is basically a group of proliferating cells in a particular part of your body. For purposes of diagnosis, a small biopsy sample will often be taken to ascertain whether the tumor is benign or malignant.

The problem is that when you stab into the cancer microenvironment to remove a part of the tissue, it creates a wound in that microenvironment that in turn elicits the invasion by macrophages and other immune cells.

If you already have an acidic microenvironment, you run the risk of causing a fusion hybridization event in that microenvironment between your macrophages and cancer stem cells (as discussed below). This could turn a potentially benign situation into a malignant one, and if the tumor is malignant, stabbing into it could make a bad situation worse.

The question is, what is the value of doing a biopsy in the first place? We take biopsies of breast tissue to get a genomic readout of the different kinds of mutations that might be in the cells. Now, if cancer is not a genetic disease and the mutations are largely irrelevant, then it makes no sense to do that in the first place. If the tumor is benign, why would you want to stab it? If the tumor is malignant, why would you ever want to stab it?

I came to this view by reading so many articles in the literature based on brain cancer, breast cancer, colon cancer, liver cancer showing how needle biopsies have led to the dissemination of these tumor cells, putting these people at risk for metastatic cancer and death,Seyfried says.

In metabolic therapy you would not touch the tumor; you would not disturb the microenvironment. By leaving it alone, you allow the tumor to shrink and go away.

When you start to look at this as a biological problem, many of the things that we do in cancer make no sense. We have, in brain cancer, people say, You have a very low-grade tumor. Lets go in and get it out. What happens is you go in and get it out, and then the following year it turns into a glioblastoma.

How did that happen? Well, you disturbed the microenvironment. You allowed these cells that are marginally aggressive to become highly aggressive. Then you lead to the demise of the patient,Seyfried says.

That happens significantly because its called secondary glioblastoma arising from therapeutic attempt to manage a low-grade tumor. The same thing can happen with all these different organs. You stab breast tumors, you stab colon tumors, you run the risk of spreading the cells

My argument is the following: If the patient has a lump, whether its in the breast, in the colon, lung or wherever or a lesion of some sort, that should be the cue to do metabolic therapy.

Do metabolic therapy first. In all likelihood, it will shrink down and become less aggressive. Then the option becomes, Should we debulk completely rather than doing some sort of a biopsy? We want to reduce the risk, because if we can catch the whole tumor completely, then we dont run the risk of spreading it

In our procedure, you bring the body back into a very high state of metabolic balance, and then you strategically go and degrade the tumors slowly without harming the rest of the body.

Radiation, chemo and the strategies that were using today dont do this. Theyre based on the gene theory of cancer that genetic mutations are causing the cell cycle to grow out of control. Well, this is not the case. Again, a lot of these toxic procedures need to be rethought, reanalyzed in my mind.

In biology, structure determines function. This is an evolutionarily conserved concept. So, how can mitochondria be structurally abnormal in tissue, yet have normal respiration? As Seyfried notes, this doesnt make sense. Confusion has arisen in part because many study cancer in culture, and make profound statements and comments regarding what happens in culture, Seyfried says.

If you look at cancer cells in culture, many of them do take in oxygen and make ATP, but at the same time, theyre fermenting. This was the conundrum. They called it the Warburg Effect. Theyre fermenting, but many people at the same time thought their respiration was normal.

This was the main problem with Warburgs theory. But Warburg clearly said in his papers [that] its not the fact that they take in oxygen; its how much ATP they can generate from oxidative phosphorylation, which is the normal respiratory capacity of the mitochondria.

As explained by Seyfried, if you measure ATP and look at oxygen consumption in tumor cells, it appears theyre making ATP and taking in oxygen, therefore, their respiration is assumed to be normal. However, when you look at the tissues in cancer patients, the mitochondria are abnormal.

What I and Dr. Christos Chinopoulos from Semmelweis University in Budapest, Hungary, who is the world-leading expert on mitochondrial physiology and biochemistry realized [was] that the mitochondria of tumor cells are actually fermenting amino acids, glutamine in particular. Theyre not respiring. Theyre fermenting an alternative fuel, which is glutamine,Seyfried says.

With this understanding, Warburgs theory can be proven correct cancer arises from damage to the mitochondrias ability to produce energy through respiration in their electron transport chain.

The compensatory fermentation involves not only lactic acid fermentation, but also succinic acid fermentation using glutamine as a fermentable fuel. Its been known for decades that glutamine is a main fuel for many different kinds of cancers, but most people thought it was being respired, not fermented.

Seyfried and Chinopoulos discovery confirms that cancer cells in fact have damaged respiration, and to survive, the cancer cells must use fermentation. The two most available fermentable fuels in the cancer microenvironment are glucose and glutamine. Hence, targeting glucose and glutamine is a crucial component of cancer treatment.

Without glucose and glutamine, the cancer cells will starve, as they cannot use ketones. The simplest approach to cancer then is to bring patients into therapeutic ketosis, and then strategically target the availability of glucose and glutamine.

Basically, what were saying [is] that mitochondrial substrate-level phosphorylation is a non-oxidative metabolism mechanism inside the mitochondria that would generate significant amounts of energy without oxidative phosphorylation,Seyfried says.

According to Seyfried, mitochondrial dysfunction is at the heart of nearly every type of cancer. Unfortunately, few oncologists have this understanding and many still believe cancer is the result of genetic defects. However, nuclear transfer experiments clearly show cancer cannot be a genetic disease.

Theres been no rational scientific argument that I have seen, to discredit the multitude of evidence showing that the [genetic] mutations are not the drivers but the effects [of mitochondrial dysfunction],Seyfried says.

As a matter of fact, theres new information now where people are finding so-called genetic drivers of cancer expressed and present in normal cells, normal skin and also esophagus This is another [issue] how you get these so-called driver mutations in normal tissues. Were also finding some cancers that have no mutations, yet, theyre fermenting and growing out of control.

There are a number of new observations coming out that challenge the concept that cancer is a genetic disease. And once you realize that its not a genetic disease, then you have to seriously question the majority of therapies being used to manage the disease. This [helps] explain [why] we have 1,600 people a day dying from cancer in the United States.

Why do we have such an epidemic of suffering and death when we have been studying this disease for decades? Well, if you look at the massive amounts of scientific papers being written on cancer, youll often find that theyre structured around gene defects.

What Im saying is that if cancer is not a genetic disease and the mutations are downstream epiphenomena, why would the field continue to focus on things that are mostly irrelevant to the nature of the disease? What Im saying is very devastating, because Im telling the majority of the people in the field that theyre basically wasting their time

I think we can drop the death rate of this disease by about 50% in 10 years if cancer is treated as a mitochondrial metabolic disease, targeting fermentable fuels rather than using toxic therapies that are focused on downstream effects.

Radiation is designed to stop DNA replication. DNA replication requires energy. If you pull the plug on their fermentable fuels, theyre not going to be able to replicate anyway All of the things that were doing to treat cancer is basically approaching the disease from a misunderstanding of the biology

We know viruses can cause cancer. We know radiation causes cancer. We know carcinogens cause cancer. We know intermittent hypoxia causes cancer. We know systemic inflammation causes cancer. We know just getting older puts you at risk for more cancer.

We know there are inherited mutations in the genome that can cause cancer. But how are all these things linked through a common pathophysiological mechanism? The common pathophysiological mechanism is damaged through the structure and function of the mitochondria.

Every one of the issues including inherited mutations, damage the respiration of a particular population of cells in a tissue. You look at the breast cancer gene (BRCA 1), for example. People will say, Cancer must be a genetic disease because you inherit a mutation that causes the disease.

You only get the disease if that mutation disrupts the function of the mitochondria. Fifty percent of women who carry the mutation never get cancer or breast cancer because the mutation, for some reason, did not damage the mitochondria in that person.

So, to summarize, the true origin of cancer is damage to the respiratory function of the mitochondria, triggering compensatory fermentation, which is run by oncogenes. Oncogenes play a role by facilitating the entry of glucose and glutamine into the cell to replace oxidative phosphorylation.

Seyfried also has a very different view on the biology of metastasis (the spread of cancer). He explains:

Weve looked at cancer stem cells in a number of our preclinical models These guys grow like crazy in place. The tumor just keeps expanding, but it doesnt spread. It doesnt spread into the bloodstream or metastasize to various organs.

We discovered a very unusual cancer 20 years ago. It took us 10 to 15 years to figure out what it was. You can put a few of these cells anywhere in the mouses body and within three to four weeks, this mouse is full of metastatic cancer. It made the cover of the International Journal of Cancer, when we published this back in 2008, but we had worked on the problem for years.

We couldnt figure out what it was that made these cells so incredibly metastatic. We found out that once we identified the biology of the cell, it turned out [it has] many characteristics in common with the macrophage, which is one of the most powerful immune cells in our body.

We said, Wow. Is this unique only to this kind of cell or do metastatic cancers in humans also express characteristics of macrophages? We looked and we found that almost every major cancer that metastasizes has characteristics of macrophages. Then we said, Well, how could this possibly happen? Is it coming from the macrophage?

A number of scientists have all clearly shown that there is some fusion hybridization character going on. In other words, macrophages, our wound-healing cells, they come into a microenvironment where you might find many proliferating neoplastic stem cells, but they dont have the capacity to metastasize.

Its only when the macrophages fuse with these stem cells that you have a dysregulated energy metabolism coming in this hybrid cell. This hybrid cell now has characteristics of both stem cells and macrophages.

The stem cell is not genetically equipped to enter and exit tissue. The macrophage, as a normal cell of your body, is genetically equipped to enter and exit tissue and live in the bloodstream. Theyre very strongly immunosuppressive. These are all characteristics of metastatic cancer.

According to Seyfried, metastatic cancer cells are essentially a hybrid, a mix of an immune system cell and a dysregulated stem cell, the latter of which could originate from a disorganized epithelial cell or something similar. In short, its a hybrid cell with macrophage characteristics.

Macrophages are essential for wound healing and part of our primary defense system against bacterial infections. They live both in the bloodstream and in tissues, and can go anywhere in the body. When an injury or infection occurs, they immediately move in to protect the tissue.

The metastatic cancer cell has many of those same properties,Seyfried explains,But the energy and the function of the cell is completely dysregulated, so it proliferates like crazy but has the capacity to move and spread through the body, so its a corrupted macrophage. We call it a rogue macrophage.

Like macrophages, metastatic cancer cells can also survive in hypoxic environments, which is why most angiogenic therapies are ineffective against metastatic cancer.

So, what do these metastatic hybrid cells need to survive? Both macrophages and immune cells are major glutamine consumers, and according to Seyfried, you can effectively kill metastatic cells by targeting glutamine.

However, it must be done in such a way so as to not harm the normal macrophages and the normal immune cells. In other words, it must be strategic. For this reason, Seyfried developed a press-pulse therapy for cancer, which allows the patient to maintain normal immune system function, while at the same time targeting the corrupted immune cells the macrophage fusion hybrid metastatic cells as well as inflammation.

The therapies we are using to attempt to kill these [metastatic] cells put us at risk for having the cells survive and kill us. You can control these cells for a short period of time, but they can hunker down and enter into some sort of a slightly dormant state, but they reappear.

People say, Oh, these tumor cells are so nifty and smart they can come back at you. The problem is youve never really challenged them on their very existence, which is they depend on fermentation to survive. If you dont target their fermentation, theyre going to continue to survive and come back at you.

Many of the therapies that we use radiation, chemo and some of these other procedures are not really going after the heart of the problem. That oftentimes puts you at risk for the recurrence of the disease. Your body is already seriously weakened by the toxic treatments. And in the battle, you lose. If you are fortunate enough to survive your body is still beat up.

You have now put your [body] at risk for other kinds of maladies Why are we using such toxic therapies to kill a cell when we know what its weaknesses are? These are the paradigm changes that will have to occur as we move into the new era of managing cancer in a logical way.

To properly address cancer, then, you need to clean up the microenvironment, because the microenvironment will strategically kill cells that are dependent on fermentation while enhancing cells that arent. At the same time, the microenvironment will also reduce inflammation.

You also have to be very careful not to kill your normal and healthy immune cells, because they need glutamine too,Seyfried says. What we find is that when we strategically attack the tumor this way, it turns out that our immune cells are paralyzed.

The cancer cells are killed, but the normal immune cells are paralyzed. Theyre not dying, theyre just not doing their job. What we do is we back off the therapy a little; allow the normal immune cells to regain their biological capacity, pick up dead corpses, heal the microenvironment, and then we go after the cancer cells again.

Its a graded response, knowing the biology of the normal cells and the abnormal biology of the tumor cells. This is a beautiful strategy. Once people know how you can play one group of cells off another, and how you can strategically kill one group of cells without harming the other cells, it really becomes a precision mechanism for eliminating tumor cells without harming the rest of the body.

You dont need to be poisoned and irradiated. You just have to know how to use these procedures to strategically kill the cells. Protecting normal macrophages is part of the strategic process. Killing the corrupted ones is part of the strategic process. Again, you have to put all of these together in a very logical path. Otherwise, youre not going to get the level of success that we should be getting.

This strategy is what Seyfried calls press-pulse treatment, and essentially involves restricting the fermentable fuels glucose and glutamine in a cyclical fashion to avoid causing damage to normal cells and tissues. Glucose is effectively restricted through a ketogenic diet. Restricting glutamine is slightly trickier.

The press-pulse strategy was developed from the concept of press-pulse in the field of the paleobiology. A press was some chronic stress on populations, killing off large numbers, but not everything, because some organisms can adapt to stress. The pulse refers to some catastrophic event.

The simultaneous occurrence of these two unlikely events led to the mass extinction of almost all organisms that existed on the planet. This was a cyclic event over many hundreds of millions of years. The geological records show evidence for this press-pulse extinction phenomenon.

What we simply did was take that concept and say, Lets chronically stress the tumor cells. They need glucose. You can probably kill a significant number of tumor cells by just stressing their glucose. Thats the press. The press is different ways to lower blood sugar. You put that chronic stress on top of the population either by restricted ketogenic diets [or] therapeutic fasting. There are a lot of ways that you can do this.

Also, emotional stress reduction. People are freaked out because they have cancer, therefore their corticoid steroids are elevated, which elevates blood sugar. Using various forms of stress management, moderate exercise all of these will lower blood sugar and contribute to a chronic press and stress on the cancer cells.

However, youre not going to kill all cancer cells if you just take away glucose. Because the other fuel thats keeping the beast alive is the glutamine. We have to pulse, because we cant use a press for glutamine targeting, because then youre going to kill your normal immune cells or impair them, and they are needed for the eventual resolution of the disease.

What were going to do is were going to pulse various drugs. We dont have a diet system that will target glutamine. Glutamine is everywhere. Its the most abundant amino acid in your body But you have to use [the drugs] very strategically; otherwise they can harm our normal immune system and then be counterproductive

I think that once we understand how we can target effectively glutamine without harming our normal immune cells this is the strategy that will make most of these other therapies obsolete Its cost-effective and non-toxic and it will work very well.

But were still at the very beginning of this. We need to continue to develop the doses, timing and scheduling of those drugs that are most effective in targeting glutamine that can be done without harming the rest of the cells in our body.

If you would like to support Dr. Seyfrieds research, please consider making a donation to the Foundation For Metabolic Cancer Therapies. The donation tag is on the top row of the of the foundationsite. This Foundation is dedicated to supporting Dr. Seyfrieds studies using metabolic therapy for cancer management with 100% of the donated funds going directly to research on metabolic therapy for cancer.

Originally published July 31, 2022 on Mercola.com

Views expressed in this article are the opinions of the author and do not necessarily reflect the views of The Epoch Times. Epoch Health welcomes professional discussion and friendly debate. To submit an opinion piece, please follow these guidelines and submit through our form here.

Go here to see the original:
Why Glucose Restrictions Are Essential in Treating Cancer - The Epoch Times

Prominent Stanford University scientist and cellular reprogramming innovator will oversee all research for Turn Bio – Yahoo Finance

Vittorio Sebastiano, globally recognized for pioneering science, expands his role at company he co-founded as it moves closer to clinical research

MOUNTAIN VIEW, Calif., Aug. 8, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced that co-founder Vittorio Sebastiano, PhD, will become its head of research.

Stanford University Professor Vittorio Sebastiano, PhD, a leader in the emerging field of cellular reprogramming, will oversee research at Turn Biotechnologies, the company he co-founded in 2018.

Sebastiano led development of the unique mRNA-based ERA (Epigenetic Reprogramming of Aging) platform Turn Bio uses to produce tailored protein cocktails to rejuvenate targeted cells. He assumes his role as head of research this month. Sebastiano has served as chairman of Turn Bio's Scientific Advisory Board since he co-founded the company in 2018.

A Stanford School of Medicine faculty member, author of more than 50 scientific articles and frequent speaker at research conferences around the world, Sebastiano is prominent in the emerging field of cellular reprogramming. His Stanford University lab pioneered the development of a new paradigm for treating aging and age-related diseases. He also led the team that first confirmed human cells can be reprogrammed using Turn Bio's ERA platform.

"Vittorio's vision and leadership will propel Turn Bio's innovation and speed our efforts to develop new therapies," said Anja Krammer, the company's CEO. "He keenly understands the potential our science has to redefine the way doctors treat age-related conditions, and shares our commitment to delivering a steady stream of new solutions to the clinic."

Sebastiano, who has conducted research at prominent universities in Europe and the United States, looks forward to bringing his academic research to life by guiding the development of Turn Bio's therapies

"The next months will be incredibly exciting, as we bridge the gap between academic science and the life-changing therapies so desperately needed by millions of people around the world," said Sebastiano. "We have the potential to cure diseases that are currently untreatable, improve the quality of life for millions and truly transform and democratize medical care."

Story continues

Sebastiano received his bachelor's and doctoral degrees from Universit di Pavia in Italy and completed post-doctoral work at the Max Planck Institute for Molecular Biomedicine in Germany and Stanford. Since 2014, he has been an associate professor of OBGyN at Stanford in the Stanford Institute for Stem Cell Biology. He is the Woods Family Scholar in Pediatric Medicine, has served as co-director of the Stanford Stem Cell PhD Program and has received prestigious awards for his pioneering and revolutionizing approach to induce cellular rejuvenation, including the 2017 American Federation for Aging Research (AFAR) Junior Investigator Award and the 2019 Breakthrough in Gerontology Award by AFAR and the Glenn Foundation.

ABOUT TURN BIOTECHNOLOGIES

Turn Bio is a pre-clinical-stage company focused on repairing tissue at the cellular level. The company's proprietary mRNA platform technology, ERA, restores optimal gene expression by combatting the effects of aging in the epigenome. This restores the cells' ability to prevent or treat disease, heal or regenerate tissue and fight incurable chronic diseases.

The company is currently completing pre-clinical research on tailored therapies targeting indications in dermatology and immunology, as well as developing therapies for ophthalmology, osteo-arthritis and the muscular system. For more information, see http://www.turn.bio.

FOR MORE INFORMATION, CONTACT:

Jim Martinez, rightstorygroup jim@rightstorygroup.comor (312) 543-9026

SOURCE Turn Biotechnologies

Here is the original post:
Prominent Stanford University scientist and cellular reprogramming innovator will oversee all research for Turn Bio - Yahoo Finance

Hisashi Ouchi Suffered an 83-day Death By Radiation Poisoning – HowStuffWorks

On the morning of Sept. 30, 1999, at a nuclear fuel-processing plant in Tokaimura, Japan, 35-year-old Hisashi Ouchi and two other workers were purifying uranium oxide to make fuel rods for a research reactor.

As this account published a few months later in The Washington Post details, Ouchi was standing at a tank, holding a funnel, while a co-worker named Masato Shinohara poured a mixture of intermediate-enriched uranium oxide into it from a bucket.

Suddenly, they were startled by a flash of blue light, the first sign that something terrible was about to happen.

The workers, who had no previous experience in handling uranium with that level of enrichment, inadvertently had put too much of it in the tank, as this 2000 article in Bulletin of the Atomic Scientists details. As a result, they inadvertently triggered what's known in the nuclear industry as a criticality accident a release of radiation from an uncontrolled nuclear chain reaction.

Ouchi, who was closest to the nuclear reaction, received what probably was one of the biggest exposures to radiation in the history of nuclear accidents. He was about to suffer a horrifying fate that would become a cautionary lesson of the perils of the Atomic Age.

"The most obvious lesson is that when you're working with [fissile] materials, criticality limits are there for a reason," explains Edwin Lyman, a physicist and director of nuclear power safety for the Union of Concerned Scientists, and co-author, with his colleague Steven Dolley, of the article in Bulletin of the Atomic Scientists.

If safeguards aren't carefully taught and followed, there's potential for "a devastating type of accident," Lyman says.

It wasn't the first time it had happened. A 2000 U.S. Nuclear Regulatory Commission report noted that before Tokaimura, 21 previous criticality accidents had occurred between 1953 and 1997.

The two workers quickly left the room, according to The Post's account. But even so, the damage already had been done. Ouchi, who was closest to the reaction, had received a massive dose of radiation. There have been various estimates of the exact amount, but a 2010 presentation by Masashi Kanamori of the Japan Atomic Energy Agency put the amount at 16 to 25 gray equivalents (GyEq), while Shinohara, who was about 18 inches (46 centimeters) away, received a lesser but still extremely harmful dose of about 6 to 9 GyEq and a third man, who was further away, was exposed to less radiation.

Internet articles frequently describe Ouchi as 'the most radioactive man in history,' or words to that effect, but nuclear expert Lyman stops a bit short of that assessment.

"The estimated doses for Ouchi were among the highest known, though I'm not sure if it's the highest," explains Lyman. "These typically occur in these kinds of criticality accidents."

The radiation dose in a criticality accident can be even worse than in a catastrophic accident at a nuclear power plant, such as the 1986 reactor explosion at Chernobyl in Ukraine, then a part of the Soviet Union, where the radiation was dispersed. (Even so, 28 people eventually died from radiation exposure.)

"These criticality accidents present the potential for delivery of a large amount of radiation in a short period of time, though a burst of neutrons and gamma rays," Lyman says. "That one burst, if you're close enough, you can sustain more than a lethal dose of radiation in seconds. So that's the scary thing about it."

High doses of radiation damage the body, rendering it unable to make new cells, so that the bone marrow, for example, stops making the red blood cells that carry oxygen and the white blood cells that fight infection, according to Lyman. "Your fate is predetermined, even though there will be a delay," he says, "if you have a high enough dose of ionizing radiation that will kill cells, to the extent that your organs will not function."

According to an October 1999 account in medical journal BMJ, the irradiated workers were taken to the National Institute of Radiological Sciences in Chiba, just east of Tokyo. There, it was determined that their lymphatic blood count had dropped to almost zero. Their symptoms included nausea, dehydration and diarrhea. Three days later, they were transferred to University of Tokyo Hospital, where doctors tried various measures in a desperate effort to save their lives.

When Ouchi, a handsome, powerfully built, former high school rugby player who had a wife and young son, arrived at the hospital, he didn't yet look like a victim of intense radiation exposure, according to "A Slow Death: 83 Days of Radiation Sickness," a 2002 book by a team of journalists from Japan's NHK-TV, later translated into English by Maho Harada. His face was slightly red and swollen and his eyes were bloodshot, but he didn't have any blisters or burns, though he complained of pain in his ears and hand. The doctor who examined him even thought that it might be possible to save his life.

But within a day, Ouchi's condition got worse. He began to require oxygen, and his abdomen swelled, according to the book. Things continued downhill after he arrived at the University of Tokyo hospital. Six days after the accident, a specialist who looked at images of the chromosomes in Ouchi's bone marrow cells saw only scattered black dots, indicating that they were broken into pieces. Ouchi's body wouldn't be able to generate new cells. A week after the accident, Ouchi received a peripheral blood stem cell transplant, with his sister volunteering as a donor.

Nevertheless, Ouchi's condition continued to deteriorate, according to the book. He began to complain of thirst, and when medical tape was removed from his chest, his skin started coming off with it. He began developing blisters. Tests showed that the radiation had killed the chromosomes that normally would enable his skin to regenerate, so that his epidermis, the outer layer that protected his body, gradually vanished. The pain became intense. He began experiencing breathing problems as well. Two weeks after the accident, he was no longer able to eat, and had to be fed intravenously. Two months into his ordeal, his heart stopped, though doctors were able to revive him.

On Dec. 21, at 11:21 p.m., Ouchi's body finally gave out. According to Lyman's and Dolley's article, he died of multiple organ failure. Japan's Prime Minister at the time, Keizo Obuchi, issued a statement expressing his condolences to the worker's family and promised to improve nuclear safety measures, according to Japan Times.

Shinohara, Ouchi's co-worker, died in April 2000 of multiple organ failure as well, according to The Guardian.

The Japanese government's investigation concluded that the accident's main causes included inadequate regulatory oversight, lack of an appropriate safety culture, and inadequate worker training and qualification, according to this April 2000 report by the U.S. Nuclear Regulatory Commission. Six officials from the company that operated the plant were charged with professional negligence and violating nuclear safety laws. In 2003, a court gave them suspended prison terms, and the company and at least one of the officials also were assessed fines, according to the Sydney Morning Herald.

Read more:
Hisashi Ouchi Suffered an 83-day Death By Radiation Poisoning - HowStuffWorks

Beam Therapeutics Announces Pipeline and Business Highlights and Reports Second Quarter 2022 Financial Results – GlobeNewswire

Patient Enrollment into BEACON Phase 1/2 Trial of BEAM-101 On-track for Second Half of 2022

BEAM-201 IND Submitted to FDA; Currently on Clinical Hold

BEAM-102 IND Submission and BEAM-301 IND-enabling Studies On-track for Second Half of 2022

John Lo, Ph.D., Appointed as Chief Commercial Officer

Ended Second Quarter 2022 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securities to Support Advancement of Broad Precision Genetic Medicines Portfolio

CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today provided pipeline and business updates and reported financial results for the second quarter ended June 30, 2022.

2022 is a critical year for Beams transition to becoming a multi-program clinical-stage company, as we prepare for the near-term initiation of patient enrollment in our BEACON Phase 1/2 trial, the first clinical trial evaluating BEAM-101 in patients with sickle cell disease, said John Evans, chief executive officer of Beam. In June, we submitted our IND for BEAM-201 for CD7-positive T-cell malignancies and recently received notification from the FDA of a clinical hold on the IND. We look forward to receiving more detail from the FDA and working with them in an effort to advance BEAM-201 for these difficult-to-treat cancer indications. We are on track to further expand our portfolio with a steady cadence of clinical and preclinical milestones expected in the quarters ahead, including the IND submission for BEAM-102, our second program in sickle cell disease, and the initiation of IND-enabling studies for BEAM-301, our first liver-directed base editing program in glycogen storage disease, both targeted in the second half of this year.

Mr. Evans added, As pioneers and leaders in the field of base editing, weve continued to extend the potential reach of our base editing technology and applications with the development of new base editors, as well as novel base editing-enabled therapeutic strategies, such as our work on non-genotoxic conditioning to improve transplant regimens. Weve also continued to enhance our team, and Im thrilled to welcome John Lo as chief commercial officer. John has a deep science background and an extensive track record in the strategic development and commercialization of novel medicines, including cell therapy products, at leading companies. I cant wait to work with him to advance our portfolio and our vision of providing a new class of precision genetic medicines to patients.

Pipeline Updates & Anticipated Milestones Ex Vivo HSC Programs

Ex Vivo T Cell Programs

In Vivo LNP Liver-targeting Programs

Recent Research Highlights

Business Updates

Second Quarter 2022 Financial Results

About Beam Therapeutics Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beams suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to, statements related to: our upcoming presentation at the 2022 International HBV Meeting; our plans, and anticipated timing, to nominate additional development candidates, initiate IND-enabling studies, submit IND applications, and initiate clinical trials; our expectation that we are on-track to further expand our portfolio with a steady cadence of clinical and preclinical milestones expected in the quarters ahead; our expectations for transitioning to a multi-program clinical stage company; the potential economic benefits that may be achieved under our amended collaboration agreement with Verve Therapeutics; the therapeutic applications and potential of our technology, including with respect to SCD and our conditioning regimens, T-ALL/T-LL, GSDIa, Alpha-1, HBV, and CAR-T cells; the expected timing of enrolling the first subject in our BEACON Phase 1/2 clinical trial of BEAM-101; the clinical hold on our BEAM-201 IND, including the FDAs communication plans related to, and our plans and expectations for interactions with the FDA and the outcomes in connection therewith; the sufficiency of our capital resources to fund operating expenses and capital expenditure requirements; and our ability to develop life-long, curative, precision genetic medicines for patients through base editing. Each forward-looking statement is subject to important risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties related to: our ability to develop, obtain regulatory approval for, and commercialize our product candidates, which may take longer or cost more than planned; our ability to raise additional funding, which may not be available; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the potential impact of the COVID-19 pandemic, including its impact on the global supply chain; the uncertainty that our product candidates, including BEAM-201, will receive regulatory approval necessary to initiate human clinical studies; uncertainty in the FDAs plans to communicate and discuss the clinical hold on the BEAM-201 IND with us and the risk that those discussions may be delayed; the uncertainty in the outcome of our interactions with the FDA regarding the clinical hold on the BEAM-201 IND; that preclinical testing of our product candidates and preliminary or interim data from preclinical studies and clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that enrollment of our clinical trials may take longer than expected; that our product candidates may experience manufacturing or supply interruptions or failures; risks related to competitive products; and the other risks and uncertainties identified under the headings Risk Factors Summary and Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2021, and in any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

Contacts:

Investors: Chelcie Lister THRUST Strategic Communications chelcie@thrustsc.com

Media: Dan Budwick 1AB dan@1abmedia.com

See the rest here:
Beam Therapeutics Announces Pipeline and Business Highlights and Reports Second Quarter 2022 Financial Results - GlobeNewswire